Patients who have had systemic anticancer therapy (e.g., chemotherapy, targeted therapy) within 3 weeks prior to entering the study
Patients must have discontinued active immunotherapy (interleukin [IL]-2, interferon, cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], etc.) or chemotherapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study; patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry
EXCLUSION - INFUSION: Currently receiving any investigational agents or radiotherapy within 4 weeks prior to entering the study
Prior treatment with lenalidomide within 8 weeks prior to entering the study
Prior and concomitant therapy:\r\n* Prior exposure to any PI3 kinase inhibitor\r\n* Exposure to chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to entering the study or lack of recovery from adverse events due to previously administered treatments\r\n* Ongoing chronic pharmacologic immunosuppression, e.g. cyclosporine, or systemic steroids that have not been stabilized to the equivalent of =< 10 mg/day prednisone prior to the start of the study drug\r\n* Other concurrent investigational agents during the study period
Patients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait 2 weeks prior to entering the study
Patients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait 2 weeks prior to entering the study; for recent experimental therapies a 28 day period of time must elapse before treatment
Patients who have had previous chemotherapy or radiotherapy for pancreatic adenocarcinoma prior to entering the study
Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study
Chemotherapy or radiotherapy within 4 weeks prior to entering the study or those with residual treatment related toxicity of greater than grade 1 not addressed in inclusion criteria
Patients who have had chemotherapy, cytotoxic therapy, immunotherapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas), surgical resection within 4 weeks prior to entering the study, or have received experimental viral therapy or gene therapy at any time (e.g., adenovirus, retrovirus or herpes virus protocol); however, this does not preclude re-treatment with M032 at a later date
Subjects who have had chemotherapy within 4 weeks prior to entering the study
Patients who have been treated with hypomethylating agents prior to entering the study are eligible
Chemotherapy, targeted therapy, biologic or hormonal agents within 3 weeks prior to entering the study
Radiation therapy within 3 weeks prior to entering the study
Patients must have completed any chemotherapy, radiation therapy, or biologic therapy >= 3 weeks prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study; patients must have recovered to eligibility levels from prior toxicity or adverse events; treatment with bisphosphonates is permitted
Patients who have had anti-cancer therapy within 2 weeks prior to entering the study
Patients must have completed chemotherapy, biological or radiotherapy >= 3 weeks prior to entering the study
Patients who have had radiotherapy within 14 days prior to entering the study
Patients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN), or ipilimumab before entering the study
Have had chemotherapy or radiotherapy within 4 weeks prior to entering the study
No prior chemotherapy or radiotherapy for the extra-ocular retinoblastoma may have been administered prior to entering this study; prior treatment (chemotherapy and/or radiation therapy) for intra-ocular retinoblastoma is permissible
Patients who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study
Radiotherapy within 4 weeks prior to entering the study
Patients must have an EKG and ECHO or MUGA scan prior to entering the study.
Patients who have had any treatment for their CLL/SLL, including but not limited to chemotherapy, radiotherapy, or immunotherapy, prior to entering the study
Patients who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study
Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study are not eligible
Patients with hemoptysis within 28 days prior to entering the study
Participants who have had chemotherapy or radiotherapy any time prior to entering the study or at any prior time for mesothelioma. Patients receiving chemotherapy type drugs for benign conditions can participate in this trial
Patients who have had radiation therapy within 1 week prior to entering the study
Patients must have discontinued active immunotherapy (interleukin [IL]-2, interferon, cytotoxic T-lymphocyte antigen 4 [CTLA-4], etc.) or chemotherapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study and have recovered from adverse events due to those agents; patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry, with the exception of vaccines
Patients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait 2 weeks prior to entering the study; for recent experimental therapies a 28 day period of time must elapse before treatment
Have had chemotherapy (including purine analogs, rituximab, and other investigational agents) within six weeks prior to entering the study
Patients who have had previous chemotherapy or radiotherapy for pancreatic adenocarcinoma prior to entering the study.
Patients who have had chemotherapy or radiotherapy to the reirradiation target within 4 weeks prior to entering the study
Patients with prior abdominal surgery within 30 days prior to entering the study
Patients with hemoptysis within 28 days prior to entering the study
Surgery involving general anesthesia, radiotherapy, steroid therapy, or immunotherapy within 4 weeks prior to vaccination. Chemotherapy within 3 weeks prior to entering the study. Palliative radiotherapy is allowable. Collection of lumenal tissue for vaccine manufacture must be avoided.
Patients who have had chemotherapy or radiotherapy to the oropharynx prior to entering the study
Patients who have had chemotherapy, biologic therapy or radiotherapy within 3 weeks prior to entering the study
Previously undergone chemotherapy, brachytherapy, or radiotherapy prior to entering the study
Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events from prior treatments
Thiazide therapy within 7 days from entering the study
Patients who have had anti-cancer systemic therapy within 2 weeks prior to entering the study; radiation is allowed
Patients who have had chemotherapy (or so-called ‘targeted’ systemic therapy), large field radiotherapy, or major surgery must wait 4 weeks after completing treatment prior to entering the study
Patients who have received chemotherapy, biological agents or investigational therapy within 4 weeks prior to entering the study
Patients who have had palliative radiotherapy within 3 weeks prior to entering the study
Patients who have received any hormonal therapy directed at the malignancy within 2 weeks prior to entering the study
Any conventional molecularly targeted therapy within 2 weeks or, chemotherapy or radiotherapy within 2 weeks (local) or 4 weeks (systemic) prior to entering the study.
Patients who have had large field radiotherapy must wait 2 weeks prior to entering the study
Patients who have had chemotherapy (other than sorafenib treatment), large field radiotherapy, or major surgery must wait 4 weeks prior to entering the study
Participants who have had surgery, chemotherapy, or radiotherapy of the sacrum prior to entering the study
Participants who have had chemotherapy, radiofrequency ablation, microwave ablation, chemo-embolization, or radiotherapy within 4 weeks prior to entering the study
Subjects who have had chemotherapy or radiotherapy within 1 week of entering the study
Patients who have had chemotherapy or other systemic therapy or radiotherapy, or those who have not recovered from adverse events due to prior administered agents as follows: chemotherapy, radiotherapy or surgery =< 3 weeks prior to entering the study, targeted therapy (e.g., TKI) =< 1 week prior to entering the study; autologous HSCT =< 6 weeks prior to entering the study; investigational drug or immunotherapy (e.g. rituximab) =< 4 weeks prior to entering the study; prophylactic intrathecal chemotherapy within one week of enrollment allowed; patients will be allowed to receive cytoreduction with hydroxyurea, 6-mercaptopurine, corticosteroids (dexamethasone, prednisone or similar) or cyclophosphamide provided that it is discontinued at least 24 hours prior to the initiation of study treatment; pre-phase treatment with dexamethasone 10 mg/m^2 (maximum total 24 mg per day) for up to 5 days is required for patients with bone marrow blasts more than 50%, peripheral blood blasts of 15,000/uL or higher, or elevated lactate dehydrogenase suggesting rapidly progressing disease as per investigator’s assessment; pre-phase treatment must be stopped at least 24 hours prior to the initiation of blinatumomab
